Stille AB (STIL.ST)
SEK 184.5
(-1.07%)
SEK 184.5
(-1.07%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 56.04 Million SEK | 31.15% |
| 2022 | 44.78 Million SEK | 55.0% |
| 2021 | 28.89 Million SEK | 81.61% |
| 2020 | 15.67 Million SEK | -54.01% |
| 2019 | 33.25 Million SEK | 18.77% |
| 2018 | 27.36 Million SEK | 31.92% |
| 2017 | 22.08 Million SEK | 9.65% |
| 2016 | 20.13 Million SEK | 45.25% |
| 2015 | 13.94 Million SEK | 195.61% |
| 2014 | 4.98 Million SEK | -24.63% |
| 2013 | 6.22 Million SEK | 535.0% |
| 2012 | 980 Thousand SEK | 153.23% |
| 2011 | 988 Thousand SEK | 132.36% |
| 2010 | -1.19 Million SEK | -117.76% |
| 2009 | 6.73 Million SEK | 4943.88% |
| 2008 | -139 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 23.37 Million SEK | -38.27% |
| 2024 Q2 | 34.87 Million SEK | 12.47% |
| 2024 Q1 | 38.17 Million SEK | 87.9% |
| 2023 Q1 | 10.49 Million SEK | 63.31% |
| 2023 Q4 | 10.68 Million SEK | -10.39% |
| 2023 FY | - SEK | 31.15% |
| 2023 Q2 | 11.94 Million SEK | 13.82% |
| 2023 Q3 | 11.92 Million SEK | -0.22% |
| 2022 Q1 | 7.99 Million SEK | 51.62% |
| 2022 Q2 | 11.25 Million SEK | 40.75% |
| 2022 Q3 | 9.45 Million SEK | -15.99% |
| 2022 FY | - SEK | 55.0% |
| 2022 Q4 | 6.42 Million SEK | -32.04% |
| 2021 Q1 | 5.94 Million SEK | 0.66% |
| 2021 Q2 | 4.38 Million SEK | -26.22% |
| 2021 FY | - SEK | 81.61% |
| 2021 Q3 | 6.53 Million SEK | 49.16% |
| 2021 Q4 | 5.27 Million SEK | -19.33% |
| 2020 Q3 | 2.15 Million SEK | 195.47% |
| 2020 FY | - SEK | -54.01% |
| 2020 Q2 | -2.25 Million SEK | -139.31% |
| 2020 Q1 | 5.72 Million SEK | -10.12% |
| 2020 Q4 | 5.9 Million SEK | 174.56% |
| 2019 Q4 | 6.37 Million SEK | -34.36% |
| 2019 FY | - SEK | 18.77% |
| 2019 Q3 | 9.71 Million SEK | 76.63% |
| 2019 Q2 | 5.49 Million SEK | -30.25% |
| 2019 Q1 | 7.88 Million SEK | 4.47% |
| 2018 Q4 | 7.54 Million SEK | 88.53% |
| 2018 Q3 | 4 Million SEK | -29.0% |
| 2018 Q2 | 5.63 Million SEK | -30.16% |
| 2018 Q1 | 8.07 Million SEK | 20.62% |
| 2018 FY | - SEK | 31.92% |
| 2017 Q1 | 4.34 Million SEK | -16.37% |
| 2017 FY | - SEK | 9.65% |
| 2017 Q3 | 3.02 Million SEK | -28.04% |
| 2017 Q4 | 6.69 Million SEK | 120.97% |
| 2017 Q2 | 4.2 Million SEK | -3.24% |
| 2016 Q1 | 4.37 Million SEK | 27.14% |
| 2016 Q2 | 3.78 Million SEK | -13.44% |
| 2016 Q4 | 5.2 Million SEK | 48.19% |
| 2016 Q3 | 3.5 Million SEK | -7.37% |
| 2016 FY | - SEK | 45.25% |
| 2015 Q4 | 3.44 Million SEK | 107.1% |
| 2015 Q3 | 1.66 Million SEK | -32.33% |
| 2015 Q2 | 2.45 Million SEK | -18.89% |
| 2015 Q1 | 3.02 Million SEK | 85.65% |
| 2015 FY | - SEK | 195.61% |
| 2014 Q4 | 1.63 Million SEK | 932.28% |
| 2014 Q1 | 344 Thousand SEK | -68.0% |
| 2014 Q2 | -166 Thousand SEK | -148.26% |
| 2014 Q3 | 158 Thousand SEK | 195.18% |
| 2014 FY | - SEK | -24.63% |
| 2013 FY | - SEK | 535.0% |
| 2013 Q4 | 1.07 Million SEK | -36.84% |
| 2013 Q3 | 1.7 Million SEK | 235.62% |
| 2013 Q2 | -1.25 Million SEK | -162.47% |
| 2013 Q1 | 2 Million SEK | 127.52% |
| 2012 FY | - SEK | 153.23% |
| 2012 Q2 | -2.25 Million SEK | -1874.8% |
| 2012 Q3 | 765 Thousand SEK | 133.94% |
| 2012 Q4 | 883 Thousand SEK | 15.42% |
| 2012 Q1 | 127 Thousand SEK | 107.96% |
| 2011 Q4 | -1.59 Million SEK | -340.36% |
| 2011 Q1 | 1.13 Million SEK | 34.28% |
| 2011 FY | - SEK | 132.36% |
| 2011 Q3 | 664 Thousand SEK | 163.18% |
| 2011 Q2 | -1.05 Million SEK | -192.84% |
| 2010 Q2 | -1.52 Million SEK | -51.84% |
| 2010 Q1 | -1 Million SEK | -151.99% |
| 2010 Q3 | -444 Thousand SEK | 70.96% |
| 2010 Q4 | 843 Thousand SEK | 289.86% |
| 2010 FY | - SEK | -117.76% |
| 2009 Q1 | 3 Million SEK | 0.0% |
| 2009 Q3 | -671 Thousand SEK | -153.51% |
| 2009 Q2 | 1.25 Million SEK | -58.31% |
| 2009 FY | - SEK | 4943.88% |
| 2009 Q4 | 1.93 Million SEK | 388.67% |
| 2008 Q2 | -2.69 Million SEK | -485.57% |
| 2008 Q1 | 700 Thousand SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 172.665% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 86.395% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 86.395% |
| Arcoma AB | 6.24 Million SEK | -796.943% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 162.28% |
| BICO Group AB (publ) | 322.3 Million SEK | 82.612% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 15.062% |
| CellaVision AB (publ) | 207.24 Million SEK | 72.959% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 181.924% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | 300.555% |
| C-Rad AB (publ) | 48.9 Million SEK | -14.594% |
| Duearity AB (publ) | -24.77 Million SEK | 326.163% |
| Dignitana AB (publ) | -264 Thousand SEK | 21327.652% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 163.901% |
| Getinge AB (publ) | 5.92 Billion SEK | 99.055% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | 183.332% |
| Iconovo AB (publ) | -35.33 Million SEK | 258.597% |
| Integrum AB (publ) | 8.76 Million SEK | -539.626% |
| Luxbright AB (publ) | -23.86 Million SEK | 334.808% |
| Mentice AB (publ) | 28.87 Million SEK | -94.095% |
| OssDsign AB (publ) | -122.02 Million SEK | 145.927% |
| Paxman AB (publ) | 31.22 Million SEK | -79.452% |
| Promimic AB (publ) | -3.68 Million SEK | 1621.2% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 137.235% |
| SciBase Holding AB (publ) | -51.82 Million SEK | 208.127% |
| ScandiDos AB (publ) | -13.35 Million SEK | 519.594% |
| Sectra AB (publ) | 615.06 Million SEK | 90.889% |
| Sedana Medical AB (publ) | -51.67 Million SEK | 208.451% |
| Senzime AB (publ) | -118.82 Million SEK | 147.163% |
| SpectraCure AB (publ) | -20.96 Million SEK | 367.256% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 101.76% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 55.725% |